GS 4182
Alternative Names: GS-4182Latest Information Update: 04 Nov 2024
Price :
$50 *
At a glance
- Originator Gilead Sciences
- Class Antiretrovirals
- Mechanism of Action Capsid protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III HIV-1 infections
Most Recent Events
- 21 Oct 2024 Phase-II/III clinical trials in HIV-1 infections (Combination therapy, Treatment-naive) in USA (PO) (NCT06613685)
- 26 Sep 2024 Gilead Sciences plans a phase II/II trial for HIV-1 infections (Treatment naive) in October 2024 (PO) (NCT06613685)
- 20 Aug 2024 Phase-II/III clinical trials in HIV-1 infections (Combination therapy) in Puerto Rico (PO) (NCT06544733)